• Home
• Responsibility
• Our values and policies
• Developing countries
• Accelerating access initiative

Accelerating access initiative

The AAI is a public-private partnership to accelerate access to care and treatment for HIV/AIDS.

GlaxoSmithKline played a leading role in its inception, announced on 11 May 2000. The AAI is a partnership between  UNAIDS, WHO, World Bank, UNICEF and UNFPA and seven research-based pharmaceutical companies - Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck and Co, Inc, and F Hoffman-la Roche. Its aim is to increase sustained access to appropriate, good quality interventions (including anti-retrovirals therapy) through new alliances involving committed governments, industry, the UN agencies, development organisations, NGOs and people living with HIV/AIDS.

It is difficult to estimate the number of patients treated as a result of our preferential pricing agreements, since GSK does not control healthcare provision. A report from the AAI, suggested that by September 2005 more than 582,000 people living with HIV/AIDS in developing countries were receiving treatment with at least one antiretroviral supplied by the seven pharmaceutical companies in the AAI compared with 221,000 people on treatment in 2004). This includes 341,000 patients in Africa. For more on GSK’s work with the AAI see accelerating access initiative.